The Food and Drug Administration (FDA) has approved Vykat™ XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome ...

Federal regulators are clearing a first-of-its-kind treatment for symptoms of a rare neurodevelopmental disorder that is ...

Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi ...

Soleno Therapeutics has won US Food and Drug Administration (FDA) approval for diazoxide choline – which will be branded as ...

Diazoxide choline is the first drug indicated for hyperphagia in the rare genetic disorder. Prior to approval, people with ...

Becoming the first treatment for rare genetic disorder Prader-Willi syndrome (PWS), breakthrough therapy drug DCCR (diazoxide choline) gained U.S FDA approval as Vykat XR the evening before March 27, ...

Vykat XR is specifically indicated to address hyperphagia, or the abnormally strong sensation of hunger, which often leads to ...

The US Food and Drug Administration (FDA) has approved Soleno Therapeutics’ (Nasdaq: SLNO) Vykat (diazoxide choline) extended ...

Soleno Therapeutics awaits FDA decision on its drug for Prader-Willi Syndrome, facing challenges amid Trump Administration's government changes.

Distinctive facial features also identify a child with Prader-Willi syndrome. These include a narrow face, almond-shaped eyes, small-appearing mouth, a thin upper lip with downturned corners of the ...

Nine-year-old Mark Allepuz-Rico was just three weeks old when his family were told the "devastating" news that he suffers from Prader-Willi syndrome - a disorder which means he needs five meals a day.

Mark Allepuz-Rico was just three weeks old when his family were told the 'devastating' news about Prader-Willi syndrome ...